Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca.

1 Jun 2015

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

The rapidly emerging field of precision medicine is a "disruptive innovation" that offers the possibility of remarkably fine-tuned remedies to improve patient health while minimizing the risk of harmful side effects, says J. Larry Jameson, MD, PhD, dean of the Perelman School of Medicine and executive vice president of the University of Pennsylvania for the Health System, in this week's issue of the New England Journal of Medicine.

1 Jun 2015

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Astellas Pharma Inc. today announced that preliminary data from a Phase 1/2 trial on the safety, tolerability and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) were presented during an oral abstract session at the American Society of Clinical Oncology's annual meeting in Chicago.

30 May 2015

Over 700 Chinese patients with acute myeloid leukemia undergo Microtransplantation treatment

According to Dr. Huisheng Ai's team, founder of Microtransplantation regimen mainly for Acute Myeloid Leukemia, over 700 patients have undergone this therapy since its emergence in 2002. Based at MST International Clinic for Leukemia in the 307th Hospital of Chinese People's Liberation Army in Beijing, about 40 hematology centers covering all main hospitals in 32 provinces of mainland China have adopted Microtransplantation regimen.

30 May 2015

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.

30 May 2015

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.

30 May 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

CTI BioPharma Corp. and Baxter International's Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill.

30 May 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.

30 May 2015

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2.

30 May 2015

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Voices Against Brain Cancer, a national non-profit organization committed to finding a cure for brain cancer and brain tumors, and the Feinstein Institute for Medical Research in Long Island, will be hosting a Brain Tumor Biotech Summit on Friday, May 29th, 2015 at Lenox Hill Hospital's Einhorn Auditorium in Manhattan.

30 May 2015

FVCG portfolio companies selected to present research at Bio International 2015

Actinobac Biomed, NovoPedics, Inc. and MentiNova, Inc., three biotech start-up companies originally funded with investments from Foundation Venture Capital Group (FVCG), have been selected to present their research at Bio International 2015 as part of the Start-Up Stadium and Company Presentation forums offered at the Conference, announced FVCG President James M. Golubieski.

30 May 2015

High CIP2A may guide TKI choice for chronic phase CML

Treatment with a second-generation tyrosine kinase inhibitor prevents progression to blast crisis in chronic myeloid leukaemia patients with high levels of cancerous inhibitor of PP2A, research suggests.

29 May 2015

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months.

29 May 2015

Study: New cases of cancer rising globally, but death rates falling in many countries

New cases of virtually all types of cancer are rising in countries globally - regardless of income - but the death rates from cancer are falling in many countries, according to a new analysis of 28 cancer groups in 188 countries.

29 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

GFG's 'A Bite for the Fight' campaign raises over $1 million for The Leukemia & Lymphoma Society

Global Franchise Group, LLC, the strategic brand management company and franchisor behind Great American Cookies, Pretzelmaker, Marble Slab Creamery, MaggieMoo's Ice Cream & Treatery, and Hot Dog on a Stick has raised more than $1 million for The Leukemia & Lymphoma Society through its "A Bite for the Fight" campaign.

26 May 2015

TGen and Baylor partnership set to increase treatment options for cancer patients

The Translational Genomics Research Institute (TGen) and Baylor Research Institute (BRI) at Dallas today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers.

22 May 2015

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform.

19 May 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

Researchers discover how and where chromosome fragile sites occur in human DNA

Using a novel method they developed to map chromosome breaks in a model organism, the budding yeast, Wenyi Feng, Ph.D., of Upstate Medical University and her colleagues have discovered new information as to how and where chromosome fragile sites can occur in human DNA. These sites are frequently observed in cancer cells and are responsible for causing genomic rearrangements.

15 May 2015

Leukemia News and Research

Further Reading

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Over 700 Chinese patients with acute myeloid leukemia undergo Microtransplantation treatment

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

FVCG portfolio companies selected to present research at Bio International 2015

High CIP2A may guide TKI choice for chronic phase CML

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

Study: New cases of cancer rising globally, but death rates falling in many countries

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

GFG's 'A Bite for the Fight' campaign raises over $1 million for The Leukemia & Lymphoma Society

TGen and Baylor partnership set to increase treatment options for cancer patients

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Researchers discover how and where chromosome fragile sites occur in human DNA

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News